ABOUT 17th_ELSF
​> REGISTRATION​
​> PRESENTERS​
​> SPONSORS​
​> SUPPORTERS​
​> NETWORKING​
> VENUE​
> ACCOMMODATION​

> ABOUT LAST YEAR​

We are pleased to announce that the 17th Annual European Life Sciences CEO Forum (Sachs_ELSF) will take place on the 28th - 29th February 2024 back at the Hilton Zurich Airport Hotel. The event will be part of the Sachs Spring Life Sciences Week, which will also incorporate the 5th Annual European HealthTech CEO Forum.  

The success and longevity of the forum is built on the goodwill and repeat attendance of major corporate and financial investors, and pharma licensing executives and advisors, who are seeking to network with biotechs. The programme and presentations allow all to keep up with the latest industry developments and strategize for 2024. The physical programme will consist of the usual panels and keynotes, which will be available on demand from the 6th of March. Additionally, there will be pre-arranged in-person meetings, live and on demand company showcases and a reception. During the online week, virtual meetings will be available through the audio/video online meeting system.

The main programme for the 17th Annual ELSF is spread throughout 2 days (28th - 29th of February) and will feature more than 12 hours of high-level keynotes and panel discussions. In addition, there will be a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand during the virtual week. We anticipate 400+ delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, banks and advisors with part of the audience participating virtually.

The In-Person meetings will be taking place on the 28th - 29th of February, while virtual meetings will take place on the 6th - 8th of March. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as the option to present slides using a screen share function and we will have a dedicated room for in-person meetings. We expect 1800+ meetings completed during SSLSW. The conference will be held in the Central European Time Zone and the programme will consist of:

Day 1 (Wednesday, 28th of February) 

• Industry Roundtable: Charting the Course for 2024
• Investment Outlook for VC & PE Panel: Focusing on Current Portfolio & Additions
• Cardiomet & Obesity Panel: Meeting the Huge Unmet Need
• Rare & Orphan Therapies Panel: Gene Therapy & Other Modalities
• Investing in NextGen ADC'S Panel
• Neuro Advances Panel: Highlighting the Main Opportunities

Day 2 (Thursday, 29th of February) 

• Greater China Biopharma Panel: Potential Role in the European Life Science Industry
• Pharma Dealmakers Panel: Viewing the Challenges from Both Sides
• Oncology BD&L Panel: Keeping Pace with Market Needs
• Cancer Progress Panel: Advances in Therapeutics & Radiopharmaceuticals
• Early-Stage Investment Panel: Addressing the Funding Need
• Rising Stars: Global Biotech Seed Session

In-Person Meetings – 28th - 29th of February 
Virtual Meetings via Online Meeting System – 6th - 8th of March  
Networking Reception – 28th of February 
On-Demand Content – from 6th of March

Confirmed Chairs & Speakers Include:

• Aksana Labokha, Head of Strategic Transaction & Business Development, Rejuveron Life Sciences AG
• Alexander Gebauer, CEO, Galimedix
• Andrea Malizia, CEO, IAMA Therapeutics S.r.l.
• Andreas Jurgeit, Partner, Gimv
• Andreas Wallnoefer, Partner, Jeito Capital
• Anna Lisa Picciolo-Lehrke, Head Business Development Neurology, UCB Pharma
• Antoine Boulanger, Senior Associate, Forbion
• Aram Mangasarian, CEO, TME Pharma AG
• Astrid Maria Dahl, COO and Head (Europe), Innovent Biologics (Europe) Limited
• Christian Thomsen, Global Head, CNS BD&L, Boehringer Ingelheim International GmbH
• Dani Bach, Partner, +ND Capital
• Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
• Dragan Grabulovski, Founder & CEO, Grabulovski Consulting Services GmbH
• Edouard Caram, Sr Director, Global Partnership Rare Diseases & Neurosciences, Ipsen
• Eric Halioua, President & CEO, PDC*line Pharma SA
• Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG
• François Thomas, Operating Partner, Quadrille Capital
• Georgia Frost, Associate, Dementia Discovery Fund - SV Health Investors LLP
  
• Helen Chen, Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner, L.E.K. Consulting
  
• Jesus Baena, BD&L Partnering Director, Novartis AG
• Juliette Audet, Partner, Forbion
• Katya Smirnyagina, Senior Partner (Life Sciences), Oxford Science Enterprises
• Khatereh Ahmadi, Head of Search & Evaluation Business Development, Europe & Middle East, MSD
• Konstantin Petropoulos, CBO & Managing Director, Secarna Pharmaceuticals GmbH & Co. KG
• Marine Beurdeley, Senior Director, Global Business Development, Ipsen
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Hübner, Director Early Innovation Partnering, Johnson & Johnson Innovation LLC
• Nathalie ter Wengel, European Lead, Worldwide Business Development, Pfizer, Inc.
• Naveed Siddiqi, Senior Partner, Novo Holdings A/S
• Nigel Sheail, Venture Partner, Versant Ventures
• Olav Zilian, Senior Equity Analyst – Healthcare, Pictet & Cie SA
• Richard Ward, Executive Director, Search & Evaluation, AstraZeneca
• Sascha Berger, Partner, TVM Capital Life Science
• Simon Chandler, CEO, Rinri Therapeutics Ltd.
• Søren Møller, Managing Partner, Novo Holdings A/S
• Stephen Myatt, CEO, Macomics Ltd.
• Susan Hill, CEO, Mestag Therapeutics Ltd.
• Tamas Schweighoffer, Co-Founding Partner, Forty51 Ventures
• Ulrich Wendt, Global Head Business Development Immunology & Inflammation, Sanofi
• Victoria English, Co-Founder & Editor, MedNous
• More TBA...

To view the full list of speakers in 2023, please click here.

PARTICIPATION OPTIONS:

Complimentary passes are provided for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however the organiser has the discretion to reject registrations. Other participants may consider purchasing access, which includes in-person or virtual participation, with different options to showcase your company. 

NETWORKING OPPORTUNITIES:

The Online Meeting System will open on the 13th of February for uploading profiles and sending meeting invites. The in-person meetings will be taking place on the 28th - 29th of February, while virtual meetings will take place on the 6th - 8th of March. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as the option to present slides using a screen share function and we will have a dedicated room for in-person meetings. 

PRESENTING OPPORTUNITIES:

Presentations are a popular and useful way to gain additional exposure with potential investors and pharma partners, which make up over half the audience. We are pleased to announce that once again we will have 20-minute and 10-minute presentations taking place in-person at the dedicated presenting tracks. Here you will be able to showcase your company in front of investors attending the physical event. The recording will be added to your company’s profile later, which will be available on demand for registered participants until the event portal closes. Start-up companies, which are looking for seed financing can apply for a Rising Stars – Seed Companies Session. 

For those who are not able to present in-person, but are still interested to showcase their company, there is an option to purchase either a 20-minute or 10-minute presentation, which will be pre-recorded in advance and available to all registered attendees on the event’s portal. Start-up companies may also purchase a 5-minute pre-recorded showcase instead.

The Sachs Team can assist with the pre-recording of the presentation, or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System.

Presenters in 2023 Included:

EXHIBITING OPPORTUNITIES: 

Make connections, engage in conversation, and exchange knowledge with key decision-makers eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at Sachs Spring Life Sciences Week is an effective way to gain leads, introduce new products and services, expand sales, and build relationships. 

If you are attending the physical event, we have a limited number of tabletop exhibitions available at the venue, restricted to three companies. These exhibitions will be located in the 'Zurich A&B' room, where the registration, breaks, and the highest attendee traffic are concentrated.

For those who are not able to join the event or exhibit in-person, you could choose virtual exhibition package, which includes a dedicated virtual page, where we can upload your branded company’s profile and list ways to reach you, share video or images about services you provide and have files ready for download if you wish to share any additional information with potential clients.

If interested in learning more about exhibition options, please fill in the registration form.

SPONSORING OPPORTUNITIES: 

There are a limited number of sponsorship opportunities for the forum, which include speaking, advertising, and branding options. Sponsors typically include investment banks and funds, large pharma, technology companies and service providers, including Stock Exchanges, IR companies, CROs, international lawyers and consulting companies. Tailored packages are available upon request. You can view the latest event’s sponsors here.

To learn more about presenting, exhibition or sponsorship opportunities, please fill in registration form or contact us at SachsTeam@SachsForum.com or by phone + 44 (0)203 463 4890.

Contributing Sponsor:

Silver Sponsor in 2023:

---

Bronze Sponsors in 2023:

---

Contributing Sponsors in 2023:

---

Supporters:

---

Participating Pharmas in 2023:

---

Financial, Advisory & Investors Attending in 2023:

+ND Capital
3B Future Health Ventures
AbbVie Ventures
Abingworth LLP
AFK & Partners Asset Management LLC
AGTC Ventures LLC
AMR Action Fund GP GmbH
Anchor
Andera Partners
Apollo Health Ventures
ARTO AG
ATGN Consulting
Atlas Capital Markets
Atlas Capital Ventures LLC
AXA Investment Managers
BERNINA BioInvest Ltd.
BGV (BioGeneration Ventures)
BioMedPartners AG
BiomedVC AG
Bioqube Ventures
BIOSTART Consulting GmbH
Boehler Life Science Advice
Bootstrap Europe
Bpifrance
Breslin AG & LSFA
BROTHERS & Partners Europe
Canica Holding AG
Capricorn Partners
CD-Venture GmbH
Columbus Venture Partners
Convergence Partners AG
Corinthian Financial Management SARL
Delin Ventures
Digital Networks Plc. S.r.l.
Eliraz Ventures
Forbion
Forty51 Ventures
FutuRx
Gimv
Global Life Science Ventures GmbH
GrayBella Capital LLC
H.C. Wainwright & Co., LLC
HBM Partners AG
High-Tech Gründerfonds Management GmbH
Hitachi Ventures GmbH
HitchinRock Advisors Limited
ICF Consult Switzerland
Indaco Venture Partners SGR
Indaco Venture Partners SGR S.p.A.
Industrifonden
Inflexion Private Equity Partners
Inveready

To View All - Click Here